Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center

• Prif Awduron: Sudha S Murthy (Awdur), D G Sandhya (Awdur), Faiq Ahmed (Awdur), K Iravathy Goud (Awdur), Monal Dayal (Awdur), K Suseela (Awdur), Senthil J Rajappa (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wolters Kluwer Medknow Publications, 2011-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Introduction: HER-2/neu status determines the eligibility for targeted therapy with trastuzumab in breast carcinoma. Evaluation for HER-2/neu protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) has become the gold standard. Aims: Since...